Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK)
HKD 0.14
(1.41%)
HKD 0.14
(1.41%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 24.12 Million CNY | -55.6% |
| 2022 | 54.34 Million CNY | 51.14% |
| 2021 | 35.95 Million CNY | -1.73% |
| 2020 | 36.59 Million CNY | -38.73% |
| 2019 | 59.71 Million CNY | 24.18% |
| 2018 | 48.08 Million CNY | -4.31% |
| 2017 | 50.25 Million CNY | -19.84% |
| 2016 | 62.69 Million CNY | 197.75% |
| 2015 | 21.05 Million CNY | -36.53% |
| 2014 | 33.17 Million CNY | -7.48% |
| 2013 | 35.85 Million CNY | 47.56% |
| 2012 | 24.29 Million CNY | 12.04% |
| 2011 | 21.68 Million CNY | 172.04% |
| 2010 | -30.1 Million CNY | 19.67% |
| 2009 | -37.47 Million CNY | -22.49% |
| 2008 | -30.59 Million CNY | -44.54% |
| 2007 | -21.16 Million CNY | 18.49% |
| 2006 | -25.96 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 19.3 Million CNY | 190.28% |
| 2024 Q2 | 18.6 Million CNY | -3.59% |
| 2023 Q2 | 13.61 Million CNY | -16.28% |
| 2023 FY | 24.12 Million CNY | -55.6% |
| 2023 Q3 | 15.62 Million CNY | 14.75% |
| 2023 Q1 | 16.26 Million CNY | -45.09% |
| 2023 Q4 | -21.37 Million CNY | -236.83% |
| 2022 FY | 54.34 Million CNY | 51.14% |
| 2022 Q4 | 29.62 Million CNY | 90.59% |
| 2022 Q1 | 10.54 Million CNY | -1.95% |
| 2022 Q2 | 6.32 Million CNY | -39.98% |
| 2022 Q3 | 15.54 Million CNY | 145.65% |
| 2021 Q1 | 15.64 Million CNY | 93.5% |
| 2021 Q4 | 10.75 Million CNY | 93.36% |
| 2021 Q3 | 5.56 Million CNY | 39.03% |
| 2021 FY | 35.95 Million CNY | -1.73% |
| 2021 Q2 | 3.99 Million CNY | -74.44% |
| 2020 Q4 | 8.08 Million CNY | -21.14% |
| 2020 FY | 36.59 Million CNY | -38.73% |
| 2020 Q1 | 9.31 Million CNY | -60.34% |
| 2020 Q2 | 8.93 Million CNY | -4.14% |
| 2020 Q3 | 10.25 Million CNY | 14.81% |
| 2019 Q3 | 17.67 Million CNY | 174.87% |
| 2019 Q2 | 6.43 Million CNY | -46.96% |
| 2019 FY | 59.71 Million CNY | 24.18% |
| 2019 Q1 | 12.12 Million CNY | -39.32% |
| 2019 Q4 | 23.49 Million CNY | 32.92% |
| 2018 Q1 | 12.72 Million CNY | -16.39% |
| 2018 FY | 48.08 Million CNY | -4.31% |
| 2018 Q4 | 19.97 Million CNY | 54.03% |
| 2018 Q3 | 12.97 Million CNY | 437.28% |
| 2018 Q2 | 2.41 Million CNY | -81.03% |
| 2017 FY | 50.25 Million CNY | -19.84% |
| 2017 Q3 | 12.56 Million CNY | 19.4% |
| 2017 Q2 | 10.52 Million CNY | -11.96% |
| 2017 Q1 | 11.95 Million CNY | -58.7% |
| 2017 Q4 | 15.22 Million CNY | 21.16% |
| 2016 Q1 | 10.03 Million CNY | 177.57% |
| 2016 Q2 | 11.37 Million CNY | 13.36% |
| 2016 Q3 | 12.34 Million CNY | 8.51% |
| 2016 FY | 62.69 Million CNY | 197.75% |
| 2016 Q4 | 28.94 Million CNY | 134.46% |
| 2015 Q1 | 10.96 Million CNY | 886.59% |
| 2015 Q2 | 2.98 Million CNY | -72.79% |
| 2015 FY | 21.05 Million CNY | -36.53% |
| 2015 Q4 | 3.61 Million CNY | 3.4% |
| 2015 Q3 | 3.49 Million CNY | 17.2% |
| 2014 FY | 33.17 Million CNY | -7.48% |
| 2014 Q2 | 11.15 Million CNY | -14.12% |
| 2014 Q4 | 1.11 Million CNY | -85.98% |
| 2014 Q3 | 7.92 Million CNY | -28.95% |
| 2014 Q1 | 12.98 Million CNY | 681.29% |
| 2013 FY | 35.85 Million CNY | 47.56% |
| 2013 Q4 | -2.23 Million CNY | -147.08% |
| 2013 Q1 | 12.04 Million CNY | 376.42% |
| 2013 Q3 | 4.74 Million CNY | -77.72% |
| 2013 Q2 | 21.29 Million CNY | 76.74% |
| 2012 Q2 | 16.38 Million CNY | 80.03% |
| 2012 Q4 | -4.35 Million CNY | -237.55% |
| 2012 Q3 | 3.16 Million CNY | -80.66% |
| 2012 Q1 | 9.1 Million CNY | 448.87% |
| 2012 FY | 24.29 Million CNY | 12.04% |
| 2011 Q3 | 20.53 Million CNY | 1272.93% |
| 2011 FY | 21.68 Million CNY | 172.04% |
| 2011 Q1 | 2.25 Million CNY | 116.3% |
| 2011 Q2 | 1.49 Million CNY | -33.57% |
| 2011 Q4 | -2.6 Million CNY | -112.7% |
| 2010 Q1 | -9.01 Million CNY | 15.35% |
| 2010 FY | -30.1 Million CNY | 19.67% |
| 2010 Q4 | -13.81 Million CNY | -893.45% |
| 2010 Q3 | 1.74 Million CNY | 119.32% |
| 2010 Q2 | -9.01 Million CNY | 0.08% |
| 2009 Q2 | -9.83 Million CNY | 0.0% |
| 2009 Q3 | -11.9 Million CNY | -21.09% |
| 2009 FY | -37.47 Million CNY | -22.49% |
| 2009 Q4 | -10.65 Million CNY | 10.49% |
| 2008 FY | -30.59 Million CNY | -44.54% |
| 2007 FY | -21.16 Million CNY | 18.49% |
| 2006 FY | -25.96 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 105.03 Million HKD | 77.03% |
| Grand Pharmaceutical Group Limited | 1.87 Billion HKD | 98.717% |
| Extrawell Pharmaceutical Holdings Limited | -162.94 Million HKD | 114.806% |
| Wai Yuen Tong Medicine Holdings Limited | -15.35 Million HKD | 257.118% |
| Qianhai Health Holdings Limited | -52.7 Million HKD | 145.777% |
| Lee's Pharmaceutical Holdings Limited | 16.69 Million HKD | -44.49% |
| Essex Bio-Technology Limited | 275.25 Million HKD | 91.235% |
| Tongfang Kontafarma Holdings Limited | -28.84 Million HKD | 183.649% |
| PuraPharm Corporation Limited | -106.08 Million HKD | 122.744% |
| SSY Group Limited | 1.31 Billion HKD | 98.17% |
| JBM (Healthcare) Limited | 130.46 Million HKD | 81.507% |
| Jacobson Pharma Corporation Limited | 266.96 Million HKD | 90.963% |
| China Resources Pharmaceutical Group Limited | 3.85 Billion HKD | 99.374% |